NLRC5 expression in tumors and its role as a negative prognostic indicator in stage III non-small-cell lung cancer patients
Open Access
- 8 July 2015
- journal article
- Published by Spandidos Publications in Oncology Letters
- Vol. 10 (3) , 1533-1540
Abstract
Major histocompatibility complex (MHC) class I molecules have a crucial role in tumor immune evasion; however, the association of MHC class I molecules with outcomes in cancer patients remains controversial. Nucleotide-binding oligomerization-like receptor family caspase recruitment domain-containing 5 (NLRC5) has been reported to be a MHC class I transactivator. However, the expression and function of NLRC5 in cancer remains to be elucidated. The present study aimed to retrospectively examine NLRC5 expression in human tumor tissues and its association with clinical outcomes of non-small-cell lung cancer (NSCLC) stage III patients. The expression of MHC class I and NLRC5 in NSCLC were detected using immunohistochemistry (IHC). The association between their expression levels was assessed using the Pearson's χ2 test and their association with survival was assessed using Kaplan-Meier analysis and the log-rank test. In addition, the expression of NLRC5 and MHC class I were examined in 323 cases of seven other types of tumors and their correlations were studied. The results revealed that the expression of NLRC5 was correlated with that of MHC class I in NSCLC patients (P=0.008). MHC class I-positive and nuclear NLRC5-positive NSCLC patients were found to have shorter overall survival (OS) rates (log-rank, P=0.032 and P=0.039, respectively). In addition, in the seven different tumor types, there was a significant correlation between MHC class I and NLRC5 nuclear expression (P<0.001) as well as MHC class I and NLRC5 cytoplasmic expression (P=0.003). In conclusion, NLRC5 was demonstrated to be widely expressed in eight tumor tissues and its expression was correlated with that of MHC class I. Of note, nuclear NLRC5-negative and MHC class I-negative stage III NSCLC patients had improved OS rates compared to those with positive expression. Therefore, NLRC5 and MHC class I may be negative prognostic indicators in NSCLC stage III patients.Keywords
This publication has 32 references indexed in Scilit:
- Expression regulation and function of NLRC5Protein & Cell, 2013
- NLRC5 Cooperates with the RFX Transcription Factor Complex To Induce MHC Class I Gene ExpressionThe Journal of Immunology, 2012
- The nucleotide-binding domain of NLRC5 is critical for nuclear import and transactivation activityBiochemical and Biophysical Research Communications, 2012
- Cross-regulation between the IL-1β/IL-18 processing inflammasome and other inflammatory cytokinesCurrent Opinion in Immunology, 2011
- Cutting Edge: NLRC5-Dependent Activation of the InflammasomeThe Journal of Immunology, 2011
- A Role for the Human Nucleotide-binding Domain, Leucine-rich Repeat-containing Family Member NLRC5 in Antiviral ResponsesJournal of Biological Chemistry, 2010
- NLRC5 Limits the Activation of Inflammatory PathwaysThe Journal of Immunology, 2010
- NLR family member NLRC5 is a transcriptional regulator of MHC class I genesProceedings of the National Academy of Sciences, 2010
- NLRC5 Negatively Regulates the NF-κB and Type I Interferon Signaling PathwaysCell, 2010
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004